Safety and Preliminary Activity of BI115 in Advanced SCLC

Summary

This study is a multi-regional, open-label phase I study to evaluate the Safety, Tolerability, and Efficacy of IBI115 as Monotherapy and in Combination Therapy in Participants with Advanced Small Cell Lung Cancer

Timeline

Start

2026-05-21

Primary completion

2028-02-29

Completion

2030-03-30

Drugs

Indications